gene in individuals relapsing following treatment While using the BCL2 antagonist venetoclax. sixty six Resistance to these brokers has become linked to these mutations in close to 70% of cases, Whilst they are frequently subclonal and their precise part causing resistance really should be established.Genetic susceptibility mechanisms. Most suscept